GHRP-6
Growth hormone-releasing peptide-6; Growth hormone releasing hexapeptide
Source type: Human study. Sources checked .
What the cited research examined
A phase-I study modeled intravenous GHRP-6 disposition in nine healthy male volunteers.
Distribution and elimination half-lives differ. These intravenous estimates do not determine a subcutaneous dosing interval.
Reference facts
- Half-life
- 2.5 ± 1.1 hoursElimination half-life in a nine-man intravenous study. A separate distribution half-life was 7.6 ± 1.9 minutes.
- Human dose range
- Not provided. This reference does not recommend a human dose.
- Administration interval
- Not established by these sources. A half-life is not a dosing schedule.
- Storage
- Product-specific information required. These sources do not establish a storage specification.
Safety context
FDA flags immune concerns and effects on glucose regulation.
Research results and substance listings are not product approvals. The FDA overview distinguishes current Category 2 entries from withdrawn nominations; withdrawal does not establish safety.
Sources and review method
- Nine-man intravenous pharmacokinetic study
- FDA: bulk substances with potential safety risks (includes withdrawn nominations)
These are bounded summaries of the linked sources, not systematic reviews. An unknown field means that these sources do not establish a general-use value. It does not claim that no other literature exists.
The calculator converts values you provide. The planner organizes entries you choose. Neither tool assesses whether a substance or schedule is appropriate.